October 2026 CHMP Opinions: Six New Medicines and What They Signal for Sponsors

The CHMP meeting of 12–15 October 2026 ended with six positive opinions for new medicines, five extensions of indication and one confirmed refusal. For anyone planning a centralised submission, the mix of products says as much as the numbers.

What the Committee recommended

According to EMA’s published highlights, the six new medicines were Rasonque (daraxonrasib) for metastatic pancreatic cancer, Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and type 2 diabetes, Yuviwel (navepegritide) for achondroplasia in children, Kizfizo (temozolomide) for glioblastoma and malignant glioma, and two biosimilars, Fovlussea (ranibizumab) and Neuzafy (filgrastim).

Two of the six are orphan medicines, two are biosimilars and two are other new products. Year to date, EMA reports 72 positive opinions for new medicines and eight negative ones.

Patterns worth noting

  • Hybrid route still delivers. Kizfizo reached an opinion through a hybrid application, a reminder that not every centralised success rests on a full new-active-substance dossier.
  • Paediatric content matters. Two opinions concern children, so agreed paediatric investigation plans and age-appropriate formulations remain central to timelines.
  • Biosimilars keep arriving. Competition in ophthalmology and supportive oncology care continues to build.

From opinion to the Greek market

A positive opinion is not the end of the regulatory journey. The European Commission decision normally follows within 67 days, after which the product is authorised in every Member State. In Greece, commercial launch then depends on national pricing, reimbursement listing and HTA steps, which should be prepared in parallel rather than after the decision.

Extensions and refusals are instructive too

Five extensions of indication received positive opinions, while the CHMP confirmed its refusal of Yartemlea (narsoplimab) after re-examination and two extension applications were withdrawn. Each outcome shows how closely the evidence package is read against the proposed wording of the indication.

How PQRA helps

PQRA supports sponsors through centralised and national procedures: dossier strategy, eCTD preparation, responses to questions, and the planning of Greek pricing and reimbursement submissions so that launch is not delayed once the Commission decision arrives.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *